What a New Prescription Follow-Up Call Should Actually Do

The new prescription follow-up call is the most commonly skipped step in an endocrinology practice, and it is the one with the shortest path to a wasted visit. The provider spent thirty minutes deciding what to send. Nobody spends thirty seconds finding out whether the patient ever picked it up.

The practice usually finds out three months later, at the next visit, when the numbers have not moved and the reason turns out to be that the medication was never started. By then the visit has been spent on a puzzle with a clerical answer. The information needed to prevent it was available within a week of the original visit, sitting in a pharmacy rejection nobody was watching.

The unfilled prescription is a front-office problem

Prescriptions going unfilled is not a rare failure at the edges of a panel. It is a routine outcome, and it is common enough that a practice should assume it rather than hope against it.

One cohort study of incident prescriptions in primary care found that 31.3% were never filled, with cost and drug class among the factors that predicted it. Endocrinology sits badly on both of those axes, because a meaningful share of what the practice sends is expensive, subject to plan restrictions, and supply-constrained.

What matters for your front office is that almost none of those reasons are clinical. The patient hit a price they did not expect. The pharmacy did not have it. The plan wanted paperwork first. Each one is a logistics failure with a known workflow attached, and each one is invisible unless somebody asks.

That is what makes this worth automating rather than staffing. The task is high volume, low judgment, and time sensitive, which is the profile of work that gets dropped first when the phones are busy.

What the call is allowed to ask

The scope of this call is narrow, and keeping it narrow is what makes it safe to run at volume.

The call establishes facts. Did you pick it up. If not, what happened when you tried. Do you know what it cost. Did the pharmacy tell you something was needed. Those are logistics questions, and the answers route to a specific queue.

The call does not discuss the medication. It does not answer whether the patient should be taking it, what it does, what to do about how they feel on it, or whether a different one would be better. Any of that goes to clinical staff with the question captured verbatim, and the patient is told a person from the practice will call back.

Drawing that line explicitly is not a compliance formality. It is the design constraint that decides what the automation is built to do, and a follow-up call built without it drifts within a week into territory that belongs to a licensed person.

Inside athenaOne the useful reference points are the patient’s medication list and the preferred pharmacy record on the chart. The first tells the automation what was sent and when. The second tells it where to expect the fill, which is the piece most practices assume is right.

The complication: the preferred pharmacy is usually wrong

The preferred pharmacy field is one of the least reliable pieces of data in the chart, and endocrinology is where that unreliability costs the most.

Patients move. Plans change their pharmacy networks at the start of the year. Specialty and mail-order requirements route certain products away from the retail pharmacy the patient actually uses, so a patient can have a correct preferred pharmacy on file and still have the prescription land somewhere they will never visit. The practice sees a sent prescription and assumes a fill is in progress.

The pattern that survives contact with this is to treat the pharmacy on file as a hypothesis rather than a fact. The follow-up call confirms where the patient actually went, and when the answer differs from the chart, that correction is the most valuable output of the call. It prevents the next three prescriptions from failing the same way.

The second complication stacks on top. Where the plan required authorization before the fill, the rejection happens at the counter, between the pharmacy and the payer, with the practice not on the thread. The patient often reads that as the medication being unavailable and stops there. Catching it means the authorization work starts in week one rather than at the next appointment, which is the entire difference between a delay and a lost quarter.

The handoff is clean at both points. The automation confirms the facts, corrects the pharmacy record, and opens the authorization task with the rejection reason attached. A person works the payer and a clinician handles anything about the medication itself.

Timing the call so it can still change something

A follow-up call has a window, and most practices place it outside that window when they place it at all.

Too early and the patient has not been to the pharmacy yet, so the call collects nothing and has to be repeated. Too late and the reason for the failure has gone stale, the patient has moved on, and the practice is now doing archaeology rather than recovery.

The useful trigger is the prescription event itself rather than a calendar date, with enough delay for a normal fill to have happened and not so much that an authorization would already be sitting untouched. Practices that run this well pick a window in the first week and hold to it.

A second contact matters more than a perfect first one. Reaching a working adult on a weekday afternoon is a coin flip, and a single unanswered call is what turns this into a program that exists on paper. A bounded sequence across different times of day, then a message with a callback path, then escalation to staff with the medication and pharmacy context already gathered, is what makes the coverage real.

What to measure, and the number that will surprise you

Two numbers make the case, and neither is call volume.

The first is the share of new prescriptions confirmed picked up within a set window. Most practices have never had this number and are startled by it, because the assumed rate and the real rate are far apart.

The second is how many pharmacy records the calls corrected. That one is a direct measure of a data problem the practice did not know it had, and it compounds, because a corrected pharmacy improves every future prescription for that patient rather than just this one.

A third worth watching is the count of authorization tasks opened in week one rather than discovered at a later visit. That is the number that translates most cleanly into visits that accomplish what they were scheduled to accomplish.

Key Takeaways

Assume a meaningful share of new prescriptions were never filled, and build the follow-up call as a standing workflow rather than an exception process.
Keep the call to logistics: picked up or not, what happened, what it cost, what the pharmacy said. Route every question about the medication to clinical staff verbatim.
Treat the preferred pharmacy record as a hypothesis. Correcting it is often the highest-value output of the call because it fixes future prescriptions too.
Trigger the call off the prescription event with a short delay, not off a calendar date, so an authorization rejection is caught in week one.
Track confirmed pickup rate and pharmacy records corrected. Call volume measures activity and tells you nothing about whether patients started therapy.

The visit is the expensive part and the follow-up call is the cheap part, which is exactly backwards from how most practices allocate attention to them. An AI team working the medication list and the preferred pharmacy record inside athenaOne can confirm what happened after the prescription was sent, fix the pharmacy data while it is on the phone, and put an authorization rejection in front of staff while there is still time to act on it.

Sources

https://pubmed.ncbi.nlm.nih.gov/24687067/